Morphic Therapeutic
OverviewSuggest Edit
Morphic Therapeutic operates as a biotechnology company. The company develops oral integrin drugs. It is advancing preclinical programs in autoimmunity, fibrosis, vascular disorders, and immuno-oncology.
| Type | Public | |
| Founded | 2015 | |
| HQ | Waltham, US | Map |
| Website | morphictx.com |
Recent NewsAll News
- Morphic Therapeutic Appoints Former Gilead Leader Norbert Bischofberger, Ph.D., to Board of Directors
- Morphic Therapeutic Enters Into Integrin Research and Development Collaboration with Janssen
- Morphic Therapeutic to Present at 37th Annual J.P. Morgan Healthcare Conference
- AbbVie and Morphic Therapeutic Announce Collaboration Targeting Fibrotic Diseases
Morphic Therapeutic Office Locations
Morphic Therapeutic has an office in Waltham
Waltham, US (HQ)
35 Gatehouse Dr
Morphic Therapeutic Financials and Metrics
Morphic Therapeutic Revenue
Morphic Therapeutic's revenue was reported to be $3.36 m in FY, 2019
| USD | |
|---|---|
Revenue (FY, 2019) | 3.4m |
Net income (FY, 2019) | (23.8m) |
EBIT (FY, 2019) | (24.6m) |
Market capitalization (8-Nov-2019) | 459.6m |
Closing stock price (8-Nov-2019) | 15.1 |
Cash (31-Dec-2018) | 185.9m |
Morphic Therapeutic's current market capitalization is $459.6 m.
| USD | FY, 2017 | FY, 2018 |
|---|---|---|
Cash | 20.8m | 185.9m |
Prepaid Expenses | 479.0k | 1.2m |
Current Assets | 21.2m | 187.1m |
PP&E | 1.7m | 1.8m |
| USD | FY, 2017 | FY, 2018 |
|---|---|---|
Net Income | (16.9m) | (23.8m) |
Depreciation and Amortization | 434.0k | 539.0k |
Accounts Payable | 285.0k | 862.0k |
Cash From Operating Activities | (15.4m) | 7.6m |
Morphic Therapeutic Acquisitions / Subsidiaries
| Acquired Company | Date | Deal Size |
|---|---|---|
| Morphic Security Corporation |
Morphic Therapeutic Online and Social Media Presence
246 Twitter followers
Morphic Therapeutic has 246 Twitter Followers. The number of followers has increased 1.7% month over month and increased 14.2% quarter over quarter
Morphic Therapeutic's Trends
Morphic Therapeutic Blogs
June 14, 2019
Morphic Therapeutic Appoints Former Gilead Leader Norbert Bischofberger, Ph.D., to Board of Directors
WALTHAM, Mass. – June 14, 2019 – Morphic Therapeutic, a biotechnology company developing oral integrin therapies, today announced the appointment of former Gilead chief scientific officer and executive vice president of research and development, Norbert Bischofberger, Ph.D., to its Board of Director…
February 21, 2019
Morphic Therapeutic Enters Into Integrin Research and Development Collaboration with Janssen
Deal extends reach of Morphic discovery across all known human integrins Therapeutic potential of Morphic pipeline expanded by inclusion of both integrin inhibitor and activator research Collaboration facilitated by Johnson & Johnson Innovation, Boston WALTHAM, Mass. – February 21, 2019 – Morphi…
January 02, 2019
Morphic Therapeutic to Present at 37th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass. – January 2, 2019 – Morphic Therapeutic, a biotechnology company developing a new generation of oral integrin therapies, announced today that the company will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 9, 2019.
October 18, 2018
AbbVie and Morphic Therapeutic Announce Collaboration Targeting Fibrotic Diseases
Collaboration leverages Morphic’s unique platform for developing oral integrin drugs and AbbVie’s global development and commercialization capabilities
NORTH CHICAGO, Ill. and WALTHAM, Mass. – October 18, 2018 – AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Morphic The…
September 25, 2018
Morphic Therapeutic Announces $80 Million Financing to Advance Next-Generation Oral Integrin Therapeutics through Clinical Proof of Concept
Series B financing led by Omega Funds and Novo Holdings
Financing to enable the initiation of IND-enabling and clinical studies in 2019
WALTHAM, Mass. – September 25, 2018 – Morphic Therapeutic, a biotechnology company developing a new generation of oral integrin therapies, announced today that it…
September 21, 2018
High integrin affinity reached by hybrid domain deletion
Check out Morphic's recent joint publication with Springer lab and see how the binding affinity and kinetics of pro-TGFβ to integrin αvβ6 are regulated by the receptor conformation. https://timothyspringer.org/publications/high-integrin-alphavbeta6-affinity-reached-hybrid-domain-deletion-slows-ligand-binding
Morphic Therapeutic Frequently Asked Questions
When was Morphic Therapeutic founded?
Morphic Therapeutic was founded in 2015.
What is Morphic Therapeutic revenue?
Latest Morphic Therapeutic annual revenue is $3.4 m.
Who are Morphic Therapeutic competitors?
Competitors of Morphic Therapeutic include KinDex Pharmaceuticals, Valneva and Therapeutic Solutions International.
Where is Morphic Therapeutic headquarters?
Morphic Therapeutic headquarters is located at 35 Gatehouse Dr, Waltham.
Where are Morphic Therapeutic offices?
Morphic Therapeutic has an office in Waltham.
How many offices does Morphic Therapeutic have?
Morphic Therapeutic has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies